STOCK TITAN

Wellington discloses passive 4.8% PTC Therapeutics (PTCT) stake in 13G/A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Wellington Management Group LLP and affiliated entities report a passive ownership position in PTC Therapeutics, Inc. common stock. As of the event date of December 31, 2025, they collectively report beneficial ownership of 3,867,380 shares, representing 4.8% of the outstanding common stock.

The filing shows no sole voting or dispositive power, with 3,316,002 shares subject to shared voting power and 3,867,380 shares subject to shared dispositive power. The shares are owned of record by clients of various Wellington investment advisers, and no single client is known to hold more than five percent of the class.

The reporting groups certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of PTC Therapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026

FAQ

What stake does Wellington report in PTC Therapeutics (PTCT)?

Wellington entities report beneficial ownership of 3,867,380 PTC Therapeutics common shares, representing about 4.8% of the company’s common stock as of December 31, 2025. This is disclosed in an amended Schedule 13G filing.

Is Wellington’s PTC Therapeutics (PTCT) position classified as passive?

Yes. The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PTC Therapeutics, consistent with a passive investment reported on Schedule 13G.

Who legally owns the PTC Therapeutics shares reported by Wellington?

The securities are owned of record by clients of one or more Wellington investment advisers. Wellington Management Group LLP and its holding entities report beneficial ownership, while individual clients have rights to dividends and sale proceeds for their respective holdings.

Does any Wellington client hold over 5% of PTC Therapeutics stock?

No. The filing states that no client is known to have the right to receive dividends or sale proceeds with respect to more than five percent of PTC Therapeutics’ common stock, based on the reported holdings.

What voting and dispositive powers does Wellington report for PTCT shares?

The Wellington entities report no sole voting or dispositive power. They report shared voting power over 3,316,002 shares and shared dispositive power over 3,867,380 shares, reflecting their role as advisers to multiple client accounts.

Which Wellington entities are reporting ownership in PTC Therapeutics (PTCT)?

The Schedule 13G/A lists Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP as reporting persons, with ownership tied to clients of several Wellington investment adviser subsidiaries.
Ptc Therapeutics

NASDAQ:PTCT

PTCT Rankings

PTCT Latest News

PTCT Latest SEC Filings

PTCT Stock Data

5.95B
78.09M
2.47%
101.79%
8.36%
Biotechnology
Pharmaceutical Preparations
Link
United States
WARREN